Valuation: Mylan N.V.

Market Cap 19.03B 16.64B 15.35B 14.18B 26.91B 1,815B 27.36B 183B 72.04B 894B 71.45B 69.89B 3,074B P/E 2026 *
70.1x
P/E 2027 * 25.9x
Enterprise Value 31.22B 27.3B 25.18B 23.26B 44.14B 2,977B 44.88B 301B 118B 1,467B 117B 115B 5,042B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 2x
Free-Float
92.23%
Yield 2026 *
3.11%
Yield 2027 * 3.19%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Tech/Sci/R&D Officer - 2023-12-14
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 19.03B
-2.46%-1.33%+49.77%+161.31% 1,085B
-1.01%-1.16%+62.55%+60.69% 624B
-1.39%-3.37%+26.25%+83.05% 442B
+0.33%-1.17%+27.98%+26.90% 332B
-3.89%-11.22%+20.78%+26.07% 277B
-0.02%-2.85%+25.27%+44.88% 282B
+0.66%-1.42%-29.26%-39.30% 217B
-0.56%-1.36%+20.34%+60.85% 196B
-3.79%+0.22%+13.41%+71.62% 167B
Average -1.06%-1.86%+24.12%+55.12% 402.44B
Weighted average by Cap. -1.54%-1.06%+34.97%+81.12%

Financials

2026 *2027 *
Net sales 14.77B 12.92B 11.92B 11.01B 20.89B 1,409B 21.24B 142B 55.93B 694B 55.47B 54.27B 2,386B 15.04B 13.15B 12.13B 11.21B 21.26B 1,434B 21.62B 145B 56.93B 707B 56.46B 55.23B 2,429B
Net income 13M 11.37M 10.49M 9.69M 18.38M 1.24B 18.69M 125M 49.2M 611M 48.8M 47.74M 2.1B 498M 435M 401M 371M 703M 47.45B 715M 4.8B 1.88B 23.38B 1.87B 1.83B 80.36B
Net Debt 12.19B 10.66B 9.83B 9.08B 17.23B 1,162B 17.52B 117B 46.13B 573B 45.76B 44.76B 1,968B 11.03B 9.65B 8.9B 8.22B 15.6B 1,052B 15.86B 106B 41.76B 518B 41.42B 40.52B 1,782B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-